Relay Therapeutics, Inc.RLAY

Relay Therapeutics, the clinical-stage small-molecule outfit that sells itself on “protein motion” and a pipeline of “previously intractable” therapies, took in just $3 million in revenue in the first three months of 2026 while torching $73.3 million in net income losses, according to its latest 10-Q. The company’s stockholders’ equity still stands at a respectable $642.2 million, but $57.4 million of that sits in current liabilities and $204.6 million is parked in cash-enough to cover about four more quarters of operating losses at the current burn rate. The cash outflow from operations clocked in at $51.1 million, a figure that does not yet include the $384,000 the company spent on property, plant, and equipment, a line item so small it barely dents the narrative of a software-heavy R&D shop.

Behind the protein-folding narrative is a company that has filed no fewer than four Form 144 notices in the past three weeks, all of them allowing insiders to sell shares in the open market. The filing trail does not say why, only that executives and affiliates have the right to do so. Relay’s own pages trumpet “proprietary capabilities” like the REL-DEL DNA-encoded library and Dynamo, its “machine learning powered” platform for identifying drug starting points, but the only thing visibly moving in July has been the pace of insider share sales. The company’s May 19 press release did crow about “initial clinical data” from the Phase 2 ReInspire trial of zovegalisib in vascular anomalies, claiming “potential for differentiated safety and efficacy,” yet the same filing that carries the press release also records a quarterly EPS of -$0.41 and an operating loss of $78.6 million.

Relay Therapeutics’ 10-Q for the quarter ending March 31, 2026, shows revenue of $3.0 million, net income attributable to parent of -$73.3 million, operating loss of -$78.6 million, assets of $699.6 million, liabilities of $57.4 million, stockholders’ equity of $642.2 million, cash and cash equivalents of $204.6 million, and net cash used in operating activities of -$51.1 million. Payments to acquire property, plant, and equipment totalled $384,000 for the prior year quarter. Earnings per share, diluted, were -$0.41. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1812364/000193280826000061/0001932808-26-000061-index.htm)

What the company actually sells-its product rail-is a blend of computational biology, machine learning, and DNA-encoded libraries, all aimed at modulating protein motion to unlock therapies that traditional methods can’t touch. The Dynamo platform and REL-DEL are the marquee tools, and the website’s splashy hero images and pipeline promises are the public face of the outfit. Yet the same pages that promise “dramatically expand[ed] therapeutic possibilities” are silent on the timing, probability, or revenue scale of those possibilities. The company’s cash runway and insider selling cadence are the only concrete realities on offer right now.

To see where the stock has traded, look at the daily volume and closing prices on your charting platform of choice; TradingView’s RLAY chart will show the price action, but the file itself carries no embedded levels or forecasts-it’s a live feed, not a prophecy. The company’s shares are listed on NASDAQ under RLAY, and the chart will reflect whatever sentiment the insider sales and quarterly filings inspire, rather than any intrinsic protein-folding magic. (source: Relay Therapeutics official site, https://relaytx.com/; SEC EDGAR company filings index, https://www.sec.gov/edgar/browse/?CIK=1812364)

The tension is simple: Relay’s story is built on a promise to redefine drug discovery via protein motion, but the numbers are still in the red. The company has not yet filed a quarterly update that shows positive net income, positive operating cash flow, or revenue growth beyond the single-digit millions. The insider selling windows are wide open, and the clinical data released so far is preliminary. Until the company converts protein motion into revenue or at least slows the cash burn, the balance sheet-not the Dynamo platform-is the only thing that matters.

What would change the file? A quarterly filing showing revenue above $10 million, positive operating cash flow, or a clear path to near-term approval for zovegalisib in any indication. Until then, the file remains a story of promise versus purse strings, with the cash ledger winning every time.